28616 Federal Register / Vol. 60, No. 105 / Thursday, June 1, 1995 / Notices

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 050895 AND 051995—Continued

Name of acquiring person, name of acquired person, name acquired entity PMN No. Dated terminated

Time Warner Inc., Time Warner Inc., The Music Sound Exchange Company ........................................................... 95–1609 05/15/95

Harbour Group Investments III, L.P., Matthew*Warren Group, Inc., Matthew*Warren Group, Inc ............................ 95–1625 05/15/95

Carlisle Companies Incorporated, Gordon F. Thomsen, Trail King Industries, Inc .................................................... 95–1569 05/16/95

Imperial Chemical Industries PLC, Grow Group, Inc., Grow Group, Inc .................................................................... 95–1574 05/16/95

Midwest Resources Inc., McLeod Inc., McLeod Inc .................................................................................................... 95–1583 05/16/95

IES Industries Inc., McLeod, Inc., McLeod, Inc ........................................................................................................... 95–1584 05/16/95

The Sherwin-Williams Company, Grow Group Inc., Grow Group Inc ......................................................................... 95–1618 05/16/95

Newell Co., Marshall S. Cogan, CHF Industries, Inc .................................................................................................. 95–1605 05/17/95

Illinois Tool Works Inc., Foamseal Inc., Foamseal Inc ................................................................................................ 95–1532 05/18/95

ConAgra, Inc., The Quaker Oats Company, Stokely-Van Camp, Inc ......................................................................... 95–1571 05/18/95

Baptist Health Systems of South Florida, Inc., South Miami Health System, Inc., South Miami Hospital, Inc., SMH

Homestead Hospital ................................................................................................................................................. 95–1575 05/18/95

Charterhouse Equity Partners II, L.P., Masada Cable Partners, L.P., Masada Cable Partners, L.P. ........................ 95–1596 05/18/95

Coram Healthcare Corporation, Lincare Holdings, Inc., Lincare Holdings, Inc .......................................................... 95–1626 05/18/95

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton,

Contact Representatives, Federal Trade

Commission, Premerger Notification

Office, Bureau of Competition, Room

303, Washington, D.C. 20580, (202) 326–

3100.

By Direction of The Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95–13362 Filed 5–31–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on

Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given,

pursuant to Title II of the Older

Americans Act Amendments of 1987,

Pub. L. 100–175 as amended by Pub. L.

102–375, and Pub. L. 103–171, that the

1995 White House Conference on Aging

Advisory Committee will hold a

meeting on Wednesday, June 14, 1995,

in Washington, DC. The general meeting

will begin at 10:00 a.m. and end at

approximately 12:00 noon. More

specific information on the location for

the meeting can be obtained by calling

the telephone number given below.

The general meeting of the Committee

shall be open to the public. The

proposed agenda includes preparation

of the proposed report of the Conference

which is to be transmitted to the chief

executive officers of the States by

August 3, 1995.

Records shall be kept of all Committee

proceedings and shall be available for

public inspection at 501 School Street

SW., 8th Floor, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT:

White House Conference on Aging, 501

School Street SW., 8th Floor,

Washington, DC 20024; telephone (202)

245–7116.

Dated: May 25, 1995.

Fernando M. Torres-Gil,

Assistant Secretary for Aging.

[FR Doc. 95–13291 Filed 5–31–95; 8:45 am]

BILLING CODE 4130–02–M

Food and Drug Administration

[Docket No. 95N–0137]

Drug Export; Antibody to Hepatitis B

Surface Antigen (Human) OrthoTM

Antibody to HBsAg Elisa Confirmatory

Test

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Ortho Diagnostic Systems, Inc., has

filed an application requesting approval

for the export of the human biological

product Antibody to Hepatitis B Surface

Antigen (human) ORTHOTM Antibody

to HBsAg ELISA Confirmatory Test to

Austria, Belgium, Canada, Denmark,

Federal Republic of Germany, Finland,

France, Iceland, Ireland, Italy, Japan,

Luxembourg, The Netherlands, New

Zealand, Norway, Portugal, Spain,

Sweden, Switzerland, and The United

Kingdom.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

human biological products under the

Drug Export Amendments Act of 1986

should also be directed to the contact

person.

FOR FURTHER INFORMATION CONTACT:

Cathy Conn, Center for Biologics

Evaluation and Research (HFM–610),

Food and Drug Administration, 1401

Rockville Pike, Rockville, MD 20852–

1448, 301–594–2006.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of human biological products

that are not currently approved in the

United States. Section 802(b)(3)(B) of

the act sets forth the requirements that

must be met in an application for

approval. Section 802(b)(3)(C) of the act

requires that the agency review the

application within 30 days of its filing

to determine whether the requirements

of section 802(b)(3)(B) have been

satisfied. Section 802(b)(3)(A) of the act

requires that the agency publish a notice

in the Federal Register within 10 days

of the filing of an application for export

to facilitate public participation in its

review of the application. To meet this

requirement, the agency is providing

notice that Ortho Diagnostic Systems,

Inc., 1001 US Hwy. 202, Raritan, NJ

08869, has filed an application

requesting approval for the export of the

human biological product Antibody to

Hepatitis B Surface Antigen (human)

ORTHOTM Antibody to HBsAg ELISA

Confirmatory Test to Austria, Belgium,

Canada, Denmark, Federal Republic of

Germany, Finland, France, Iceland,

Ireland, Italy, Japan, Luxembourg, The

Netherlands, New Zealand, Norway,

Portugal, Spain, Sweden, Switzerland,

and The United Kingdom. The Antibody

to Hepatitis B Surface Antigen (human)